RxDoctor Payments DataLook up a doctor →

Sanju Varghese, MD

Nephrology · Springfield, OHNPI 1780629956

Payments from drug & device makers

$84,414in general payments, 2019–2025

Across 510 payments — averaging $165.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$51K
  • Vantive US Healthcare LLC$27K
  • Amgen$1K
  • Novartis$831
  • Bayer$449
  • Mallinckrodt Hospital Products Inc.$360
  • plus $4K from 31 others

What the payments were for

  • Consulting fees$2,4434%
  • Speaking & faculty fees$42,97575%
  • Travel & lodging$2,3214%
  • Food & beverage$8,92716%
  • Education$8491%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,414 in reported general payments places this provider in the 90th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$230,808
Medicare patients
475
Services billed
2,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan13$268,957
FarxigaDapagliflozin Propanediol192$221,545
KerendiaFinerenone92$86,264
JardianceEmpagliflozin61$79,094
OzempicSemaglutide40$37,791
LokelmaSodium Zirconium Cyclosilicate38$28,910
DapagliflozinDapagliflozin Propanediol31$14,777
ClinolipidFat Emulsion/Olive/Soy/Phospho48$12,419
Cinacalcet Hcl15$10,013
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$9,323
Sevelamer Carbonate44$4,457
Torsemide156$4,007
ProsolParenteral Amino Acid 20% No.129$3,579
Potassium Chloride182$3,319
Metolazone110$3,067

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$274$268,95713 claims
AstraZenecaFarxiga, Lokelma$50,729$250,455230 claims
BayerKerendia$449$86,26492 claims
Boehringer IngelheimJardiance$179$79,09461 claims
Novo NordiskOzempic$207$37,79140 claims
GSKTrelegy Ellipta$66$9,32311 claims
ANI Pharmaceuticals, Inc.Valsartan$186$51321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 nephrology providers in Ohio.

Other nephrology in Springfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →